Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Racial disparity of epidermal growth factor receptor expression in prostate cancer.

Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C, Cordon-Cardo C, Taneja SS, Osman I.

J Clin Oncol. 2004 Dec 1;22(23):4725-9. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570072
2.

Altered N-myc downstream-regulated gene 1 protein expression in African-American compared with caucasian prostate cancer patients.

Caruso RP, Levinson B, Melamed J, Wieczorek R, Taneja S, Polsky D, Chang C, Zeleniuch-Jacquotte A, Salnikow K, Yee H, Costa M, Osman I.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):222-7.

3.
4.

Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F.

Clin Cancer Res. 2002 Nov;8(11):3438-44.

5.

Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.

Jia RP, Xu LW, Su Q, Zhao JH, Li WC, Wang F, Xu Z.

Asian J Androl. 2008 Sep;10(5):758-64. doi: 10.1111/j.1745-7262.2008.00423.x.

6.

The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates.

Pan CC, Lee JS, Chan JL, Sandler HM, Underwood W, McLaughlin PW.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1292-6.

PMID:
14630264
7.

Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.

Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5377-84.

8.

Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.

Prtilo A, Leach FS, Markwalder R, Kappeler A, Burkhard FC, Cecchini MG, Studer UE, Thalmann GN.

J Urol. 2005 Nov;174(5):1814-8; discussion 1818.

PMID:
16217293
9.

The independent impact of extended pattern biopsy on prostate cancer stage migration.

Master VA, Chi T, Simko JP, Weinberg V, Carroll PR.

J Urol. 2005 Nov;174(5):1789-93; discussion 1793.

PMID:
16217288
10.

Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment.

Fowler JE Jr, Bigler SA, Bowman G, Kilambi NK.

J Urol. 2000 Jan;163(1):137-42.

PMID:
10604331
11.

Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status.

Vijayakumar S, Weichselbaum R, Vaida F, Dale W, Hellman S.

Cancer J Sci Am. 1996 Jul-Aug;2(4):225-33.

PMID:
9166537
13.

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S.

J Clin Oncol. 2004 Dec 1;22(23):4772-8. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570078
14.

Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity.

Underwood W 3rd, Wei J, Rubin MA, Montie JE, Resh J, Sanda MG.

Urol Oncol. 2004 Jan-Feb;22(1):20-4.

PMID:
14969799
15.

Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.

Sarkaria IS, Zakowski MF, Pham D, Hezel M, Ebright MI, Chuai S, Venkatraman ES, Kris MG, Rusch VW, Singh B.

Ann Thorac Surg. 2008 Jan;85(1):216-23.

PMID:
18154814
16.

Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients.

Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B, Zeleniuch-Jacquotte A, Polsky D, Ferrara J, Perez-Soler R, Cordon-Cardo C, Pagano M, Osman I.

Clin Cancer Res. 2003 Jul;9(7):2613-9.

17.

Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer.

Ohara S, Oue N, Matsubara A, Mita K, Hasegawa Y, Hayashi T, Usui T, Amatya VJ, Takeshima Y, Kuniyasu H, Yasui W.

Cancer Sci. 2008 Aug;99(8):1570-7. doi: 10.1111/j.1349-7006.2008.00846.x.

18.

African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men.

Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA.

Cancer. 2006 Jul 1;107(1):75-82.

19.
20.

Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.

Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FH, Haese A, Kollermann J, Graefen M, Huland H, Sauter G, Simon R, Erbersdobler A.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6579-84.

Supplemental Content

Support Center